You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
再鼎醫藥(09688.HK)獲Mirati抑製產品獨家授權
阿思達克 06-02 09:49
再鼎醫藥(09688.HK)公布,與Mirati Therapeutics, Inc.(MRTX.US),公司將有權在大中華區(中國內地、香港、澳門及台灣)研究、開發、製造及獨家商業化小分子KRASG12C抑製劑adagrasib。

公司將向Mirati支付6,500萬美元的預付款,Mirati可收支高達約2.73億美元的潛在里程碑付款及高百分之十幾至低百分之二十幾的分級授權金。

再鼎醫藥將支持adagrasib在關鍵全球性支持註冊的臨床研究,以加速KRAS G12C突變癌症患者的入組,而Mirati可選擇在大中華區共同商業化adagrasib ,並保留adagrasib在大中華區以外所有國家和地區的全面和獨家權利。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account